8:01 AM ET
8-K
Investor Presentation
Ocugen Investor Presentation
Ocugen, Inc. filed a formal investor presentation deck for October 2026 detailing its strategic pipeline and clinical milestones. The company is targeting three Biologics License Applications (BLAs) by 2028 for its gene therapy candidates OCU400, OCU410, and OCU410ST, which address major blindness diseases.